| Name | Title | Contact Details |
|---|---|---|
John Burke |
Sr. Director of Information Technology and Electronics | Profile |
Endocyte Inc is a West Lafayette, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. The Cabaletta Approach to selective B cell Ablation (CABA™) platform, in combination with Cabaletta`s proprietary technology, utilizes CAAR T cells that are designed to selectively bind and eliminate only specific autoantibody-producing B cells while sparing normal antibody-producing B cells, which are essential for human health. The Company`s lead product candidate, DSG3-CAART, is being evaluated in the DesCAARTes™ phase 1 clinical trial as a potential treatment for patients with mucosal pemphigus vulgaris, a prototypical B cell-mediated autoimmune disease. The FDA granted Fast Track Designation for DSG3-CAART in May 2020. For more information about the DesCAARTes™ Phase 1 clinical trial, please visit our website ( DesCAARTes™ Phase 1 Trial ). The Company`s lead preclinical product candidate, MuSK-CAART, is in IND-enabling studies and is designed as a potential treatment for patients with MuSK-associated myasthenia gravis.
As a CDMO our focus is to combine technical leadership in cell culture, microbial fermentation and viral vectors with world class cGMP manufacturing facilities to advance tomorrow`s medicines. For over 25 years our focus has been on supporting our customers with the development and manufacture of recombinant proteins, viral vaccines and gene therapies.
RNAimmune is a biotechnology startup in the field of messenger RNA (mRNA) technology with more than 20 years expertise in handling and optimizing this versatile molecule for medical purposes. The principle of RNAimmune`s proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. The company applies its technologies for the development of cancer therapies, antibody therapies, the treatment of rare diseases, and prophylactic vaccines.
OraPharma , Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.